Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
137 Leser
Artikel bewerten:
(0)

Global Gene Expression Market 2017-2021 - Key Vendors are Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche & Thermo Fisher Scientific

DUBLIN, August 30, 2017 /PRNewswire/ --

The "Global Gene Expression Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global gene expression market to grow at a CAGR of 10.56% during the period 2017-2021.

Global Gene Expression Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is emergence of advanced genome editing techniques and genetic screening programs. A high precision and cost-effective technique, CRISPR-Cas9, is a game-changing form of gene editing and is dispersing throughout biotech laboratories and biotech start-ups globally. It has enormous potential as it can detect mutations at the granular level in the human genome, thus creating highly sophisticated results.

According to the report, one driver in the market is decreasing cost of DNA sequencing. Since DNA sequencing is an essential step in the gene expression protocol, researchers consider the cost of sequencing as an essential parameter when designing their experiments. In the past, after the completion of the human genome project, sequencing techniques involved several trial and error methods, and thus, the resultant cost of the technique was high, resulting in huge cost burden for researchers. However, this scenario has changed drastically due to advancements in science and molecular biology.

Further, the report states that one challenge in the market is shortage of trained healthcare professionals in genomics. Gene expression techniques are highly technical in nature and care must be taken at each step to facilitate a successful experiment and generate reproducible results. It is doubtful whether healthcare professionals in the global genomics market are competent enough to make sense of the huge amount of genomic data being generated from multiple experiments undertaken globally. Priorities in national healthcare systems, access to genomic technologies, and differences in education and training systems among countries further contribute to the inconsistent understanding of genomic data.

Key vendors



  • Agilent Technologies
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific

Other prominent vendors

  • Fluidigm
  • GE Healthcare Dharmacon
  • Illumina
  • Interpace Diagnostics
  • Miltenyi Biotec
  • New England BioLabs
  • OriGene Technologies
  • Oxford Nanopore Technologies
  • PerkinElmer
  • Phalanx Biotech Group
  • Promega
  • QIAGEN
  • Zyagen

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Segmentation By Application

Part 07: Market Segmentation By Product

Part 08: Geographical Segmentation

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Key Vendor Analysis

Part 14: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4pj6h7/global_gene


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.